What Goes On Inside Your Boardroom? Investors Want To Know
Public M&A Day in Frankfurt
Global Dealmaking in 2013: Why the Best Strategies will Dominate
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention - Overall, pharma, medical...more
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
After two years of pandemic caution and amid perpetually increasing valuations, growing piles of dry powder and pent-up investment willpower, 2021 exploded in a global deal frenzy unrivaled in the past decade. On the heels of...more
While global dealmaking in Q1 was down from a blockbuster 2021, there are signs deal activity could pick up later in the year - Following a record-breaking year for dealmaking, 2022 has had a relatively slow start. A total...more
Australian M&A returned to full power in 2021, following a dip in activity in 2020 as the pandemic took hold. Deal activity within the country exceeded even the most ambitious predictions, with a total of US$256 billion in...more
A rebound in European corporate transactions has driven a double-digit acceleration in leveraged finance earmarked for M&A (excl. buyouts), with a robust pipeline setting the stage for an active 2022. In the summer of...more
M&A markets appeared to defy gravity through 2021. Globally, dealmakers were highly active, with values exceeding US$5 trillion for the first time ever. Total deal value rose by 81 percent on 2020 totals to US$5.75 trillion,...more
Interest in high-growth industries such as TMT and financial services resulted in a string of deals—from both local and international bidders. Egyptian dealmaking delivered a strong performance in 2021. A total of US$6.7...more
After four quarters in a row of exceptionally high PE activity, Q3 2021 has continued the trend, recording the highest value and volume of any third quarter on record - The summer months of July and August typically mean...more
Despite a drop on the previous quarter, Q3 2021 global M&A value represented the strongest Q3 on Mergermarket record - The third quarter is usually a sleepy one for M&A—but not so this year. A total of US$1.4 trillion in...more
The region’s burgeoning digital economy is drawing attention from investors across the globe - The value of deals taking place in Southeast Asia reached a new high in the first half of 2021. Deals worth US$101.6 billion...more
After a turbulent 18 months which saw M&A crash before an impressive return to form, H2 2021 is set for continued strong deal activity, as well as new challenges - US M&A progressed steadily through the first half of 2021....more
The value of healthcare M&A in H1 surpassed pre-pandemic levels - Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more
Williams: Court of Chancery Finds Poison Pill Unenforceable - In February, the Delaware Court of Chancery held that a shareholder rights plan (a "poison pill") adopted by The Williams Companies, Inc. at the onset of the...more
A brightening macroeconomic outlook and supportive deal environment helped push second-quarter value to a new record Dealmakers hoping for a 2021 rebound in M&A activity have not been disappointed. In Q2 2021, M&A value...more
Soaring demand in high-growth industries is causing a steady flow of PE investment into the sector - While 2020 was a tumultuous year for global dealmaking, private equity (PE) activity within the consumer sector finished...more
There have been a number of developments in merger control in 2020 and Q1 2021. Some are related to the repercussions of the COVID-19 pandemic, while others are borne out of the ambitions and changes sought by individual...more
After a challenging 2020, APAC private equity dealmakers are forging ahead with deals, and financing markets are well-positioned to support the revival - Private equity (PE) firms in the Asia-Pacific region are...more
After nearly a decade of growth, global M&A activity in the first quarter of 2020 was down 39.1% by deal value year over year — comparable to levels seen in the first quarter of 2008, in the midst of the financial crisis. The...more
Navigating the ever-changing global life sciences deal landscape has become more challenging in the post-pandemic world. Conducting virtual inspections and examining security and privacy risks for remote working and new...more
How will the election affect life sciences in 2021 and beyond? What’s ahead for the regulatory and policy environment? In this session, our elite group of policy analysts reviewed the election results and the far-reaching...more
In a climate where there are so many unknown factors challenging valuation methodologies, we explore a number of mechanisms that European dealmakers may consider during the Coronavirus (COVID-19) pandemic in order to bridge...more
M&A in Vietnam surged in Q3, thanks to an economy that has proved resilient in the face of a global pandemic - M&A in Vietnam has been remarkably robust in 2020. The total volume of deals over the first three quarters of...more
The energy transition and a growing need for efficient digital infrastructure are two trends fueling infrastructure dealmaking in 2020 - In a year that has seen global M&A activity drop significantly, M&A within the...more
Deal activity fell dramatically in 2020, but Q3 shows signs of recovery - Global dealmaking slowed dramatically in 2020, as the world grappled with the health, economic and political consequences of the COVID-19 pandemic....more